Combination clinical trials with idelalisib in patients with NHL
OR indicates overall response; PFS, progression-free survival; R/R, relapsed/refractory; NHL, non-Hodgkin's lymphoma; CR, complete response; FL, follicular lymphoma; SLL, small lymphocytic lymphoma; and MCL, mantle cell lymphoma.
Sign In or Create an Account